TP53 and head and neck squamous cell carcinoma: But the patients in the high ATPscore group were more likely to have a TP53 mutation, again indicating the role of ATPscore in predicting the ICIs immunotherapy response, as mutation status of TP53 could have predictive value for immunotherapy in patients with HNSCC [63].